Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC-7366 in Acute Myeloid Leukemia
NCT06285890Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HC-7366 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events. Started May 2024; status: recruiting.
02
Drugs
HC-7366
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06285890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285890.